Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Musculoskeletal | Rheumatology
Clinical Trials: Osteoporosis
A listing of clinical trials currently looking for volunteers to enroll in Osteoporosis studies. Click on the closest city to find more detailed information on a research study in your area.
Arizona
Tucson : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
California
Anaheim : Anaheim Clinical Trials (ACT)
Are you concerned about Osteoporosis?
Walnut Creek : Diablo Clinical Research
Could you have thinning bones or osteoporosis?
Walnut Creek : Diablo Clinical Research
Do You Have Osteoporosis?
View More »
Anaheim : Anaheim Clinical Trials (ACT), 1085 North Harbor Blvd.
Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Postmenopausal Women With Low Bone Mineral Density
La Mesa : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Laguna Hills : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Long Beach : Long Beach Memorial Medical Center
Clinical Evaluation of the Crosstrees Pod™ in the Treatment of Pathologic Fracture of the Vertebral Body (Levels T4 - L5) in Adult Patients
San Diego : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
San Francisco : UCSF Imaging Center
Assessment of Bone Micro-Architecture Using HR-pQCT
San Luis Obispo : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Walnut Creek : Research Site
Transition From Alendronate to AMG 785
Colorado
Denver : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Lakewood : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Lakewood :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Connecticut
Middlebury : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
New Britain : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Florida
Clearwater : Advanced Imaging & Interventional Institute
Clinical Evaluation of the Crosstrees Pod™ in the Treatment of Pathologic Fracture of the Vertebral Body (Levels T4 - L5) in Adult Patients
Daytona : Orthopedic Clinic of Daytona Beach
Clinical Evaluation of the Crosstrees Pod™ in the Treatment of Pathologic Fracture of the Vertebral Body (Levels T4 - L5) in Adult Patients
Fort Lauderdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Hollywood : Broward Spine Institute
Clinical Evaluation of the Crosstrees Pod™ in the Treatment of Pathologic Fracture of the Vertebral Body (Levels T4 - L5) in Adult Patients
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
View More »
Miami : Seaview Research Inc., 3898 NW 7th Street,
Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Postmenopausal Women With Low Bone Mineral Density
Miami :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Naples : Physician's Regional Healthcare System
Clinical Evaluation of the Crosstrees Pod™ in the Treatment of Pathologic Fracture of the Vertebral Body (Levels T4 - L5) in Adult Patients
Trinity : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Georgia
Hawaii
Honolulu : Research Site
Transition From Alendronate to AMG 785
Idaho
Coeur d'Alene : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Illinois
Chicago : Ruth M Rothstein CORE Center
Study of Bone Disease in Older HIV-infected Adults
Indiana
Greenwood : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Iowa
West Des Moines : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kansas
Overland Park : Pfizer Investigational Site
Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.
Louisiana
Shreveport : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Maryland
Annapolis : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Baltimore : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Bethesda : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Bethesda :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Bethesda : Research Site
Transition From Alendronate to AMG 785
View More »
Greenbelt : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Massachusetts
Boston : Massachusetts General Hospital
Testosterone and Alendronate in Hypogonadal Men
Boston : Massachusetts General Hospital
The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
Michigan
Detroit : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Minnesota
Sartell : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Missouri
St Louis : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Montana
Missoula : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Nebraska
Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Omaha : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
New Jersey
Berlin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Englewood : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Mount Laurel : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
New York
Garden City : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Syracuse : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
North Carolina
North Dakota
Bismarck : St. Alexius Medical Center
Clinical Evaluation of the Crosstrees Pod™ in the Treatment of Pathologic Fracture of the Vertebral Body (Levels T4 - L5) in Adult Patients
Fargo : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Ohio
Cincinnati : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Upper Arlington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Pennsylvania
Bala Cynwyd : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Duncansville : Research Site
Effects of Denosumab on the Pharmacokinetics of Etanercept
Duncansville : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Lancaster : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Philadelphia : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
South Carolina
Myrtle Beach : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Tennessee
Knoxville : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Texas
Dallas : Research Site
Effects of Denosumab on the Pharmacokinetics of Etanercept
Denton : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
San Antonio : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Virginia
Richmond : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Richmond : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Salem : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Washington
Renton : Rainier Clinical Research Center
Have you been diagnosed with osteoporosis or experience the risk factors for osteoporosis?
Australia
Herston : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Nedlands : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Wahroonga : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Westmead : Novartis Investigative Site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Austria
Belgium
Brussels : Novartis Investigative Site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Laeken : Novartis Investigative Site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Brazil
Rio de Janeiro :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Bulgaria
Plovdiv : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Sofia : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Canada
Barrie : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brampton : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brantford : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Burlington : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Calgary : Novartis Investigative site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
View More »
Edmonton : Novartis Investigative site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Guelph : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Halifax : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Halifax : Novartis Investigative site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Hamilton : Novartis Investigative site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Hamilton : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Kelowna : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kitchener : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Laval : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
London : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Montreal : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Montreal : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Montreal : Novartis Investigative site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Montreal : Mcgill University Health center
The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.
Newmarket : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
North Bay : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Oakville : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Ottawa : Novartis Investigative site
1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Ottawa : Novartis Investigative site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Quebec : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Sherbrooke : Centre hospitalier universitaire de Sherbrooke
Strategies to Treat Osteoporosis Following a Fragility Fracture
St. John : Novartis Investigative Site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Toronto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Toronto : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Toronto : University Health Network, TGH
Teriparatide (PTH) and Bone Strength in Postmenopausal Women
Vancouver : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Vancouver : Novartis Investigative site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Vancouver : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Victoria : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Winnipeg : Novartis Investigative site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Croatia
Czech Republic
Benesov : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brno : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brno : Site Ref # / Investigator 32407
Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis
Brno :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Hlucin : Site Ref # / Investigator 48404
Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis
View More »
Jindrichuv Hradec : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kromeriz : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Novy Jicin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Olomouc : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Pardubice :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Prague : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Praha 2 : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Praha 4 : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Praha 6 : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Usti nad Labem : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Zlin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Denmark
Aalborg : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Aalborg :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Aarhus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Ballerup :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Hvidovre : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
View More »
Kobenhavn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Odense : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Odense : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Odense : Department of Endocrinology
Study of Male Osteoporosis and Aging
Vejle : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Vejle :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Estonia
Tallinn : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Tallinn :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Tartu : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Tartu :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Finland
Helsinki : Novartis Investigative Site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Kuopio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Oulu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Turku : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
France
Angers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
La Roche Sur Yon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Lyon : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Orleans : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
View More »
Paris : Cochin hospital
Effects of Proteins Fraction Derived From Milk on Osteoporosis Prevention
Paris Cedex 5 : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Germany
Bamberg : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Berlin : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Bielefeld : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Bochum : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Bogen : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
View More »
Dresden : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Essen : Department of Internal Medicine III, Alfried Krupp Krankenhaus Essen Steele
Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy
Heidelberg : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Kassel : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Leipzig : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Leverkusen : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Marburg :
A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis
Marburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Minden : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Siegen : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Stuttgart : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Greece
Alexandroupoli : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Athens : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Heraklion : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kifissia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Larissa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
View More »
Larissa : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Patra : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Thessaloniki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Hong Kong
Hong Kong :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Hungary
Baja : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Budapest : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Budapest : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Gyor : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Nyiregyhaza : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
View More »
Szeged : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
India
Ahmedabad : GSK Investigational Site
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Bangalore : GSK Investigational Site
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Delhi : GSK Investigational Site
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Mangalore : GSK Investigational Site
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Nagpur : GSK Investigational Site
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
View More »
Pune : GSK Investigational Site
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Trivandrum : GSK Investigational Site
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Ireland
Italy
Cagliari : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Firenze : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Milano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Palermo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
View More »
Verona : Policlinico GB Rossi
Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis
Japan
Bungo-Ono :
Study of AK156 in Primary Osteoporosis Patients
Chiba :
Study of AK156 in Primary Osteoporosis Patients
Fukuoka :
Clinical Study of AK159 in Healthy Postmenopausal Women
Fukuoka :
Study of AK156 in Primary Osteoporosis Patients
Inami-cho :
Study of AK156 in Primary Osteoporosis Patients
View More »
Kagoshima :
Study of AK156 in Primary Osteoporosis Patients
Kikukawa :
Study of AK156 in Primary Osteoporosis Patients
Kumamoto :
Study of AK156 in Primary Osteoporosis Patients
Kure :
Study of AK156 in Primary Osteoporosis Patients
Many Locations :
Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
Many Locations :
Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan
Many Locations : Updated
Wellnara Post-marketing Surveillance in Japan
Matsumoto :
Study of AK156 in Primary Osteoporosis Patients
Miyazaki :
Study of AK156 in Primary Osteoporosis Patients
Morioka :
Study of AK156 in Primary Osteoporosis Patients
Oyama :
Study of AK156 in Primary Osteoporosis Patients
Sapporo :
Study of AK156 in Primary Osteoporosis Patients
Sendai :
Study of AK156 in Primary Osteoporosis Patients
Setagaya :
Study of AK156 in Primary Osteoporosis Patients
Shinagawa :
Study of AK156 in Primary Osteoporosis Patients
Tokorozawa :
Study of AK156 in Primary Osteoporosis Patients
Tonami :
Study of AK156 in Primary Osteoporosis Patients
Tosu :
Study of AK156 in Primary Osteoporosis Patients
Yokohama :
Study of AK156 in Primary Osteoporosis Patients
Korea, Republic of
Busan : GSK Investigational Site
A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Daegu : GSK Investigational Site
A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Gwangju : GSK Investigational Site
A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Many Locations :
Angeliq Regulatory Post Marketing Surveillance
Seoul : GSK Investigational Site
A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
View More »
Seoul : GSK Investigational Site
BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)
Seoul : GSK Investigational Site
BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )
Seoul : The Catholic University of Korea Seoul St. Mary's Hospital
Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis
songpa-gu, Seoul : GSK Investigational Site
A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Suwon : GSK Investigational Site
A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Suwon : Ajou University Hospital
Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women
Latvia
Jelgava : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Riga : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Lithuania
Vilnius :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Mexico
Distrito Federal : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Distrito Federal : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Monterrey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
New Zealand
Auckland : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Christchurch : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Christchurch : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Takapuna, North Shore City : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Tauranga : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
View More »
Whangarei : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Norway
Poland
Gdansk : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Gdynia : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Katowice : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Lodz :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Myslowice : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
View More »
Opole : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Poznan : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Szczecin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Warsaw : Novartis Investigative Site
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Warszaw :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Warszawa : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Wroclaw : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Puerto Rico
Romania
Bucharest :
Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women
Russian Federation
Ivanovo : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Moscow : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Nizhny Novgorod : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Rostov-na-Dony : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Slovakia
Banska Bystrica : Site Ref # / Investigator 46084
Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis
Bratislava : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Bratislava : Site Ref # / Investigator 46082
Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis
Kosice : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kosice : Site Ref # / Investigator 46083
Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis
View More »
Martin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Nitra : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Piestany : Site Ref # / Investigator 46085
Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis
Tornala : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Slovenia
Ljubljana : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
South Africa
George : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kempton Park : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Paarl : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Paarl : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Port Elizabeth : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
View More »
Tygerberg : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Spain
Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Barcelona : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Madrid : Research Site
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis
Sevilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Sweden
Malmo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Mölndal : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Stockholm : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Uppsala : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Thailand
Bangkok : MSD (Thailand) Ltd.
Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)
United Kingdom
Bristol : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Nottingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Oxford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
Penarth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study That Will Compare the Effect of Two Drugs on Patients With Low Bone Mass and a Recent Hip Fracture
United States
Washington : The George Washington University Hospital
Clinical Evaluation of the Crosstrees Pod™ in the Treatment of Pathologic Fracture of the Vertebral Body (Levels T4 - L5) in Adult Patients
